Novartis: immunocellular cancer drug gets EU approval
(CercleFinance.com) - Swiss drugmaker Novartis said on Monday the European Commission has approved its CAR-T cell therapy Kymriah that uses a patient's own T cells to fight cancer.
Brussels has approved Kymriah for the treatment of pediatric and young adult patients of up to 25 years of age with B-cell acute lymphoblastic leukemia and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, Novartis said.
As a reminder, Kymriah has been the first CAR-T cell therapy ever approved by the US Food and Drug Administration.
Kymriah involves reprogramming a patient's own T-cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing cells. It is administered as an intravenous infusion.
Last Friday, Novartis issued data from a study presented at the European Society of Cardiology (ESC) Congress in Munich, showing that heart drug Entresto can be initiated early and safely in a wide range of heart failure patients with reduced ejection fraction who have been stabilised after hospitalisation due to acute heart failure.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Brussels has approved Kymriah for the treatment of pediatric and young adult patients of up to 25 years of age with B-cell acute lymphoblastic leukemia and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, Novartis said.
As a reminder, Kymriah has been the first CAR-T cell therapy ever approved by the US Food and Drug Administration.
Kymriah involves reprogramming a patient's own T-cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate CD19-expressing cells. It is administered as an intravenous infusion.
Last Friday, Novartis issued data from a study presented at the European Society of Cardiology (ESC) Congress in Munich, showing that heart drug Entresto can be initiated early and safely in a wide range of heart failure patients with reduced ejection fraction who have been stabilised after hospitalisation due to acute heart failure.
Copyright (c) 2018 CercleFinance.com. All rights reserved.